Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoproteasome caspase-like site beta 1i (LMP2)
- Target
- LMP2
- Molecular classification
- Enzyme, Protease, Proteasome subunit
01
Overview
The immunoproteasome caspase-like site beta 1i, also known as LMP2, is a proteolytic enzyme subunit within the 20S core particle of the immunoproteasome. It replaces the constitutive beta 1 subunit in cells exposed to pro-inflammatory cytokines like interferon-gamma. Its primary role is to modify peptide generation for MHC class I antigen presentation, thereby influencing adaptive immune responses. While possessing caspase-like activity (cleavage after acidic residues), this activity is reduced compared to the constitutive beta 1 subunit. Inhibition of beta 1i is explored therapeutically in autoimmune diseases and cancer.
- Other names
- LMP2PSMB9Beta 1i subunit of immunoproteasome
02
Mechanism of action
Inhibition of caspase-like proteolytic activity within the immunoproteasome
03
Biological functions
Antigen processingPeptide generation for MHC class I presentationProtein degradation
04
Disease associations
AutoimmunityCancerInfectionInflammation
05
Safety considerations
Potential for altered immune cell functionOff-target effects due to similarity with other proteasome subunits
06
Interacting drugs
Amide compound 7
1 more in the full profile.
Beyond the preview
Go deeper on Immunoproteasome caspase-like site beta 1i (LMP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoproteasome caspase-like site beta 1i (LMP2).